Study of Faricimab Injection for Treating Subretinal Hyperreflective Material in Patients With Type 2 or Mixed Neovascular Age-Related Macular Degeneration

What this Trial Is About

Researchers are studying the effectiveness of Faricimab Vabysmo4, an injectable humanized antibody, in treating patients aged 50 and older with subretinal hyperreflective material SHRM associated with type 2 or mixed neovascular membranes in age-related macular degeneration AMD. This phase IV clinical trial aims to determine the percentage of patients who experience resolution of SHRM by week 16. The study is conducted in ophthalmology clinics in Spain and focuses on a rare subtype of macular neovascularization where SHRM is common. Participants will receive Faricimab at a dose of 6 mg0.05 ml via intravitreal injection, following the approved product guidelines. The study involves a single experimental arm where all patients are treated with Faricimab. This drug targets two pathways by neutralizing Ang-2 and VEGF-A and may help stabilize neovascular membranes and reduce SHRM through its dual inhibitory action. During the study, participants will undergo multimodal imaging to assess the resolution of SHRM at week 16. Researchers will monitor visual acuity and retinal health through various assessments to evaluate treatment effects. The total duration includes follow-up to confirm the primary outcome measure. Safety and adherence will be observed throughout, with participants providing informed consent before enrollment.

Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material